Extent of disease:\r\n* Patients with non-metastatic and metastatic disease are eligible\r\n* Initially unresectable patients, with or without metastatic disease, are eligible as long as there is a commitment at enrollment to resect the primary tumor
Patients with more than 3 discrete locations of extra-cranial metastatic disease after first-line systemic therapy requiring more than 3 radiation/surgery plans to cover these distinct metastatic disease entities.
Have a history of an invasive metastatic disease, except for the following:
Individuals with a history of invasive metastatic disease are eligible if they have been disease free for at least 2 years and are deemed by the Investigator to be at low risk for recurrence of that metastatic disease;
Presence of metastatic disease (stage IV NSCLC) is not allowed; subjects must be evaluated with a CT or PET scan prior to registration for protocol therapy to exclude metastatic disease
Known spinal cord compromise or instrumentation due to metastatic disease. Radiation therapy for metastatic disease is allowed.
Metastatic CRPC
Known metastatic disease
Any patient with metastatic disease.
Patient does not have metastatic disease
Confirmed metastatic disease
PHASE IB: =< 2 lines of prior systemic therapy for metastatic disease (if patients have metastatic disease)
Diagnosis of metastatic disease
Presence of metastatic disease
Known metastatic disease
Metastatic disease
Prior radiation treatment for metastatic disease
For patients with metastatic disease:
Known metastatic disease
Any metastatic disease
Widely metastatic disease (oligometastatic disease acceptable)
Metastatic disease.
Patients may have received one prior hormonal treatment for metastatic disease
Metastatic CRC
Metastatic disease or local-regional disease that is considered not resectable for cure
Has metastatic disease
Patients with more than >= 3 metastatic lung lesions or any one lesion greater than 5 cm and/or extensive metastatic disease outside the chest
Patient has had at least one prior systemic therapy for metastatic disease
Has metastatic disease
Metastatic
Metastatic disease
Patients must not have known metastatic disease
Patients with metastatic disease will not be excluded
Patients with metastatic disease
The subject has metastatic disease at the time of screening
No metastatic disease (M0)
Presence of metastatic disease on scans
Patient has stage N1 or M1 (metastatic) disease
Known metastatic disease
Metastatic disease outside of the liver
Known metastatic disease
Presence of metastatic disease
Known metastatic disease
Multi-focal or metastatic disease
Known metastatic disease
Metastatic disease on pretreatment imaging
Known metastatic disease
Metastatic disease
History, presence, or suspicion of metastatic disease
Patients with metastatic disease
Metastatic disease
Presence of metastatic disease
Metastatic disease
Patients with Gilbert's disease or known CNS metastatic disease.
Metastatic disease
Other metastatic melanoma systemic disease allowed
Have received at least one prior therapy for metastatic disease
Presence of metastatic disease
Diagnosis of metastatic disease
Patients with metastatic disease
No more than two prior therapies for metastatic disease
Patients must have metastatic disease
Patients must have pathologically or radiologically confirmed metastatic disease in the brain
Chest x-ray negative for metastatic disease
Patients with metastatic disease must have received at least one line of standard of care (SOC) treatment for metastatic disease prior to enrollment
History of metastatic disease at any time or presence of detectable metastases.
Metastatic disease involving bone with metastatic disease previously confirmed by prior biopsy; or Metastatic disease involving bone previously confirmed on imaging (e.g. CT or MRI) with known (biopsied) primary disease (primary bone cancer is excluded)
Prior systemic therapy for metastatic disease
Have histologically or cytologically diagnosed oligo-metastatic prostate cancer; oligo-metastatic disease is defined to reflect men with low volume disease; specifically, oligo-metastatic disease is defined as less than 5 extra-pelvic metastases; metastatic lesions may be lymph nodes
Known metastatic disease
Metastatic disease
Presence of metastatic disease (stage IV NSCLC) is not allowed. Subjects must be evaluated with a PET scan within 28 days prior to registration for protocol therapy to exclude metastatic disease
Have metastatic disease
Metastatic disease
Have metastatic disease
Documentation of metastatic disease
Metastatic disease
Imaging confirmation of metastatic disease
Patient presents with Stage 4 pulmonary metastatic disease with metastatic disease previously confirmed by prior biopsy; or Patient presents with Stage 4 pulmonary metastatic disease previously confirmed on imaging (e.g. computerized tomography or CT) with histology proven primary cancer.
At least one prior treatment for metastatic disease
Any metastatic disease
Patients with prior surgical resection who develop radiological or clinical evidence of metastatic cancer do not require separate histological or cytological confirmation of metastatic disease unless an interval of > 5 years has elapsed between the primary surgery and the development of metastatic disease; clinicians should consider biopsy of lesions to establish diagnosis of metastatic disease if there is substantial clinical ambiguity regarding the nature or source of apparent metastases
Advanced or metastatic disease
Patient has known metastatic disease
I 02. Metastatic disease.
Patients should have at least one organ system involved with distant metastatic disease; if only a single metastatic lesion is present, biopsy is mandatory
Patients with metastatic disease
Presence of extra-cranial metastatic disease
Group A: Metastatic disease, myeloma, lymphoma;
No prior systemic therapy for metastatic disease.
Patients with metastatic disease
Advanced metastatic disease
Metastatic disease
Patients with known metastatic disease are excluded
Pathologically (histologically or cytologically) confirmed metastatic disease with a new tumor involving or abutting bone that has the clinical and imaging features of metastatic disease\r\n* If the nature of the metastatic disease has been previously documented, index tumor to be treated does not require further documentation (i.e., biopsy)
Treatment with erlotinib prior to developing metastatic disease
Metastatic disease.
Prior systemic therapy for metastatic disease.
Patients must have demonstrated metastatic disease and not received > 2 lines of chemotherapy for metastatic disease (N/A for phase II)
Presence of metastatic disease to the bone
The patient has another metastatic cancer disease.
Metastatic disease outside of liver
Patients with metastatic disease
Patients with metastatic disease (BREAST ONLY)
Patients with metastatic disease
Presence of metastatic disease
Diagnosis of pathologically confirmed metastatic pancreatic, hepatobiliary, esophageal, or lung cancer, either newly metastatic or metastatic at presentation (M1+) and enrollment within 6 weeks of diagnosis; measurable disease need not be present
Any spinal cord compromise or instrumentation due to metastatic disease; radiation therapy for metastatic disease is allowed
Presence of metastatic disease
Presence of metastatic disease
Patients who have known metastatic disease or other bulk disease in the thoracic or cervical regions
Metastatic disease of any kind
Subject with metastatic disease
Known metastatic disease
Informed of metastatic disease within the previous 8 weeks
No prior therapy for metastatic disease
Presence of metastatic disease
There is no limit to the amount of prior therapy for metastatic disease
Patients with metastatic disease
Metastatic disease
Patients with metastatic disease
Metastatic disease
Plan to start a new systemic therapy for metastatic disease
Patients with known metastatic disease
Patients with any metastatic disease
Patients with known metastatic disease
Patients with metastatic disease
Have confirmed metastatic disease
Patient: Does not have metastatic disease
Does not have metastatic disease